To evaluate the impact of androgen deprivation therapy (ADT) on prostate volume, lower urinary tract symptoms (LUTS), and LUTS-related quality of life (QOL) in patients with prostate cancer. Methods: Patients with prostate cancer (PCa) were treated with goserelin and bicalutamide for 24 weeks. Changes in the total prostate volume (TPV), International Prostate Symptom Score (IPSS), and QOL score for urinary symptoms were assessed every 12 weeks. Of the 42 patients enrolled, 8 patients withdrew and 2 were excluded, so 32 patients were analyzed. Results: The median age, PSA levels, and TPV were 77.5 years, 22.0 ng/mL, and 29.5 cm 3 , respectively. TPV showed a significant decrease from baseline in weeks 12 and 24, with the mean percent decreases being −37.5 ± 4.25 and −7.5 ± 3.84%, respectively. The IPSS decreased from baseline to weeks 12 and 24 (from 11.7 ± 1.6 to 9.3 ± 1.0 and 9.3 ± 1.0; P = 0.15 and 0.2, respectively). The IPSS voiding score showed a significant decrease from baseline to weeks 12 and 24 whereas the IPSS storage score did not. In patients with moderate to severe LUTS, the IPSS and the QOL score showed a significant decrease in weeks 12 and 24. In patients with mild LUTS, nocturia increased significantly from baseline and there was approximately one additional episode of nocturia at 24 weeks. Conclusions: In this study, we observed that ADT significantly reduced TPV and improved LUTS in patients with PCa and moderate to severe LUTS, but increased nocturia in patients with mild LUTS.
INTRODUCTION
The hormone-responsive nature of prostate cancer (PCa) means that it can be treated effectively with agents that reduce the stimulation of androgen-sensitive pathways, either by blocking the androgen receptor or by decreasing the production of testosterone. Androgen deprivation therapy (ADT) is not only cytostatic but also cytotoxic for hormone-sensitive PCa cells and thus has a strong influence on tumor growth and viability. 1 Luteinizing hormone-releasing hormone (LHRH) agonists are the most widely used form of ADT. 2 Chronic administration of LHRH agonists eventually results in downregulation of the LHRH receptor. This, in turn, suppresses pituitary LH and follicle-stimulating hormone (FSH) secretion and testosterone production, so that testosterone decreases to castration levels, usually within 2-4 weeks. 3 Anti-androgens act by a different mechanism, competing with testosterone and 5-α-dihydrotestosterone at the receptor level in the tumor cell nucleus to promote apoptosis and inhibit tumor growth. 4 ADT is the mainstay of management for advanced PCa. Recently, there has also been a move towards increasing use of ADT in patients with earlier disease or recurrence after definitive treatment, either as single-agent therapy or as part of a multimodal approach. 2 In patients with advanced PCa, combined androgen blockade (CAB), which involves adding an anti-androgen agent to either surgical or pharmacological castration, appears to provide some survival advantage over monotherapy, although this remains debatable. 5, 6 In almost 70% of patients with PCa, the disease arises from the peripheral zone of the prostate gland and causes local symptoms, lower urinary tract symptoms (LUTS), only when the cancer has grown to compress or invade proximate structures such as the prostatic urethra, the urinary bladder, or the neurovascular bundles. 7 Another reason for the onset of LUTS in patients with PCa is the parallel increase in prostate volume due to benign prostatic hypertrophy (BPH), which increases in prevalence with age 8 . According to Lehrer et al., 9 55.6% of PCa patients have mild LUTS, 37.1% have moderate symptoms, and 7.3% have severe symptoms.
Because ADT reduces the prostate volume as well as the tumor volume, it may relieve LUTS in patients with PCa. In fact, some PCa patients with acute urinary retention have been reported to regain the ability to void after bilateral orchiectomy. 10 However, there have been few studies of the impact of ADT on prostate volume, changes in LUTS, and quality of life (QOL) for urinary symptoms in PCa patients. We investigated the effects of 24 weeks of CAB, focusing on changes in total prostate volume (TPV), LUTS, and QOL related to urinary symptoms.
MATERIALS AND METHODS
This was a prospective single-arm study with the following inclusion criteria: age >40 years, histologically confirmed PCa (any stage), no contraindications to ADT, with a screening serum PSA level >4 ng/mL, and an estimated life expectancy of at least 12 months. Patients who received neoadjuvant ADT before radiation therapy or who could not receive a radical treatment, such as radical prostatectomy or radiation therapy, because of comorbidities, were also included. Exclusion criteria were previous treatment for PCa or surgery for BPH, an indwelling urinary catheter, treatment with a 5-α reductase inhibitor or anti-androgen agent, or planned radiotherapy during the study period. Patients who had started or changed α-1 blockers or anti-cholinergic agents within 3 months before the study were also excluded. In addition, starting or changing α-1 blockers or anti-cholinergic agents during the study was not permitted.
This study was carried out in compliance with the Helsinki Declaration and the Good Clinical Practice guidelines. The institutional ethics committee approved the protocol.
Eligible patients received treatment with goserelin and bicalutamide for 24 weeks. Goserelin implants were inserted subcutaneously into the abdominal wall at a dose of 3.6 mg/month (10.8 mg/3 months), while oral bicalutamide (80 mg once daily) was started on day 0 and continued throughout the study.
Baseline evaluation of the patients included a medical history, medications, vital signs, electrocardiography, European Cooperative Oncology Group performance score (ECOG PS), and details of their cancer (including TMN stage and Gleason score). Blood and urine samples were collected and tests were done to establish untreated baseline values for key efficacy and safety variables.
Total prostate volume was measured by transrectal ultrasound (ALOKA SSD-1000, Hitachi Aloka Medical, Tokyo, Japan), with the procedure being standardized according to the manufacturer's manual, and was calculated by an elliptical approximation (width × height × length × π /6). TPV was assessed every 12 weeks during the study. The severity of LUTS was assessed by the International Prostate Symptom Score (IPSS) questionnaire, which has been used in similar studies.
11 Mild LUTS were defined as an IPSS of 1-7, moderate LUTS was an IPSS of 8-19, and severe LUTS was an IPSS of 20-35. 12 The IPSS voiding score was calculated as the sum of the responses to question 1 (incomplete emptying), question 3 (intermittency), question 5 (weak stream), and question 6 (straining), while the storage score was calculated as the sum of the responses to question 2 (frequency), question 4 (urgency), and question 7 (nocturia). The IPSS was assessed every 12 weeks. The score for QOL related to urinary symptoms was assessed from the eighth IPSS question. Patients were asked to rate their condition on a scale of 0-6 (corresponding to delighted, pleased, mostly satisfied, mixed, mostly dissatisfied, unhappy, and terrible).
Blood samples to measure PSA were collected every 12 weeks before drug administration and PSA levels were determined by a validated chemiluminescence method. Safety and tolerability were assessed from laboratory data (biochemistry tests, hematology tests, and urinanalysis) and clinical variables (implantation site tolerability, adverse events [AEs], physical examination, and vital signs).
The primary efficacy outcome measures were the mean percent reduction of TPV and the change in IPSS from baseline to weeks 12 and 24. Patients who did not complete the entire study were excluded from the analysis. Changes in the variables were analyzed by the Wilcoxon matched-pairs signed-rank test. Predictors of improvement in LUTS were investigated with the χ 2 test, Student's t-test, Mann-Whitney U-test, and using logistic regression models. All analyses were performed using the SPSS software (ver. 19.0 for Windows; IBM SPSS statistics, IBM Japan, Tokyo, Japan). Results are shown as means ± standard error of the mean (SEM) unless otherwise indicated and P < 0.05 was considered to indicate statistical significance.
RESULTS
The disposition of the patients is shown in Figure 1 . Of the 42 patients enrolled, 34 patients completed the study and 8 patients withdrew for the following reasons: 4 wished to discontinue treatment due to adverse effects, 2 had protocol deviations, 1 died of an unrelated cause, and 1 was lost to follow-up. Another 2 patients were excluded from analysis because of the lack of TPV data at 12 or 24 weeks, so 32 patients were analyzed. A profile of the patients is shown in Table 1 . Their median age, PSA levels, and TPV were 77.5 years (range, 66-85), 22.0 ng/mL (7.6-1370), and 29.5 cm 3 (16.0-82.1), respectively. Of the patients, eight (25.0%), nine (28.1%), 13 (40.6%), and two (6.3%) had T1, T2, T3, and T4 tumors, respectively. In addition, 10 (31.3%), 17 (53.1%), and 5 (15.6%) patients had tumors with Gleason score 6 or less, 7, and 8 or more, respectively. Twelve patients were already being treated with α-1 blockers and one was using an anticholinergic agent at enrollment.
Total prostate volume showed a significant decrease from baseline at weeks 12 and 24 (from 34.7 ± 3.15 to 20.7 ± 2.2 and 17.5 ± 1.9 cm 3 , respectively; P < 0.0001, vs. baseline), with the mean (±standard error) percent decrease being −37.5 ± 4.25% at week 12 and −47.5 ± 3.84% at week 24 (Fig. 2) . The difference in TPV between weeks 12 and 24 was also statistically significant (P < 0.0001). When a significant TPV reduction was defined as a −30% decrease, 22 (68.8%) and 29 patients (90.6%) experienced a significant TPV reduction at weeks 12 and 24. Age was a predictive factor for a significant TPV reduction at week 12 (75.5 ± 0.9 in patients with a significant TPV reduction versus 79.4 ± 1.8 in others, P = 0.04), but TPV and PSA at baseline, T stage, and Gleason score were not. PSA decreased significantly from baseline at weeks 12 and 24 (from 136.4 ± 52.4 to 3.1 ± 2.4 and 1.5 ± 1.3 ng/mL, respectively; P < 0.0001, vs. baseline).
The present study had no specified baseline IPSS and thus LUTS varied widely, as follows: 14 (44%) patients had mild symptoms, 11 (34%) had moderate symptoms, and 7 (22%) had severe symptoms. The changes in IPSS are shown in Figure 3 . The total score decreased from baseline at weeks 12 and 24 (from 11.7 ± 1.6 to 9.3 ± 1.0 and 9.3 ± 1.0, respectively) with a mean decrease of 2.4 at both times, although the differences were not significant (P = 0.15 and 0.21, vs. baseline, respectively). The IPSS voiding score showed a significant decrease from baseline at weeks 12 and 24 (from 5.8 ± 1.0 to 3.4 ± 0.5 and 3.6 ± 0.6, respectively; P < 0.05, vs. baseline). In contrast, the IPSS storage score was not significantly different from baseline at week 12 or 24 (from 6.0 ± 0.7 to 5.9 ± 0.6 and 5.7 ± 0.5, respectively; P = 0.22 and 0.16, vs. baseline). The QOL score for urinary symptoms tended to decrease from baseline at week 12 (from 3.1 ± 0.3 to 2.6 ± 0.3; P = 0.053), but not at week 24 (to 2.8 ± 0.2; P = 0.26, vs. baseline). The percentage of patients showing clinically meaningful improvement in LUTS (i.e., a decrease in the IPSS total score by at least three points) was 37.5% at week 12 and 31.3% at week 24.
To identify predictors of clinically meaningful improvement, we performed univariate and multivariate analyses with the age, PSA, TPV, Gleason score (GS), T stage, ECOG PS, and IPSS at baseline as variables. When we defined patients with a decrease in IPSS of at least three points at weeks 12 or 24 as responders and the others as non-responder, GS and IPSS total score were significant predictors of response in univariate analyses (Table 2) . In logistic regression models, only IPSS was independently associated with a meaningful IPSS response (odds ratio = 2.002, 95% CI = 1.164-3.442, P < 0.05).
The changes in TPV and IPSS in patients with moderate to severe LUTS (IPSS at baseline ≥8, n = 18) versus those with mild LUTS (IPSS at baseline 1-7, n = 14) are shown in Figure 4 . In patients with moderate to severe LUTS, the IPSS showed a significant decrease from baseline at weeks 12 and 24 (both P < 0.05, vs. baseline) along with the decrease in TPV (Fig. 4a,b) . In these patients, the IPSS voiding score also decreased significantly from baseline at weeks 12 and 24 (with mean decreases of −4.5 and −4.1, respectively; both P < 0.01, vs. baseline), whereas the IPSS storage score did not change significantly (Fig. 4c,d) . The QOL score also showed a significant decrease from baseline at weeks 12 and 24 (P < 0.01 and < 0.05, vs. baseline, respectively; Fig. 4f ). In contrast, the IPSS showed a tendency to increase from baseline at week 12 (P = 0.08, vs. baseline) in patients with mild LUTS, despite a decrease in TPV (Fig. 4a,b) . In these patients, the IPSS storage score was significantly higher at week 12 than before treatment (P < 0.05, vs. baseline; Fig. 4d ). In particular, the score for question 7 of the IPSS (nocturia) increased significantly from baseline at weeks 12 and 24 (from 1.7 ± 0.2 to 2.2 ± 0.2 and 2.7 ± 0.4, respectively, P < 0.05 and < 0.01, vs. baseline). There was approximately one additional episode of nocturia at week 24 relative to baseline (Fig. 4e) . However, the QOL score did not change significantly (Fig. 4f) . Safety was assessed in all 42 enrolled patients. Treatment-emergent AEs were reported in 16 (38.1%) patients. Most AEs were mild or moderate. Common treatment-emergent AEs were hot flushes in six patients, subcutaneous bleeding in four, and depressed mood, fatigue, and cognitive dysfunction in two each. AEs that led to discontinuation of the study and were (possibly) related to treatment were depressed mood, hot flushes, cognitive dysfunction, and lumbar compression fracture in one patient each. The incidence of markedly abnormal laboratory findings or vital signs was low (data not shown). The two serious AEs were a fatal ruptured aortic aneurysm and de novo lung cancer, but both were considered to be unrelated to treatment.
DISCUSSION
We assessed the influence of ADT (goserelin plus bicalutamide) on TPV and changes in LUTS and IPSS-related QOL over a 24-week treatment period. Several previous studies have demonstrated that the reduction in TPV achieved by ADT is around 30-50%, and that CAB has a stronger effect on TPV compared to LHRH agonist monotherapy, whereas it has a similar effect to the LHRH antagonist degarelix. 13 -17 In the present study, a mean reduction of −37.5% was seen in TPV after 12 weeks of CAB and a further −10.0% occurred from 12 to 24 weeks (Fig. 2) , consistent with previous studies. A mean 37.5% reduction of TPV after 3 months of CAB is a superior outcome to the reported decrease of approximately 25% that was achieved over 24 months of treatment with 5-α reductase inhibitors, which are commonly used in BPH patients with prostatomegaly (TPV > 30 mL). 18 Large prostate volume is reported to be associated with comorbidity in robot-assisted radical prostatectomy (i.e., longer operative time, increased blood loss, urinary leakage rate, longer hospital stay, decreased continence rate after prostatectomy). 19, 20 A reduction in prostate volume by ADT may decrease the comorbidity of prostatectomy in patients with an enlarged prostate although this has not been demonstrated.
In the present study, 35% of patients experienced meaningful LUTS relief after ADT. Particularly in patients with moderate to severe symptoms, ADT significantly improved urinary symptoms, particularly voiding symptoms, along with an improvement in urinary QOL (Fig. 4b,c,f) . This alleviation of LUTS emerged during the first 12 weeks of treatment with no further improvements thereafter. Mommsen and Petersen 10 reported a 62% success rate for urethral catheter removal after bilateral orchiectomy in PCa patients with acute retention. Axcrona et al. 17 reported that administration of goserelin or degarelix for 3 months improved urinary symptoms in PCa patients. In that study, advanced age was negatively associated with LUTS relief whereas high log PSA and use of degarelix were associated with improvement of symptoms. In the present study, IPSS at baseline and GS were significant predictors of LUTS relief in univariate analyses and TPV had also a tendency to be associated with LUTS relief (Table 2) . It has been demonstrated that GS correlates with tumor volume and bladder neck invasion in PCa, 21 -23 and that 17% of tumors were in continuity with the urethra and the distance between tumor and urethra correlated negatively with GS. 24 Thus, a tumor with a high GS may have a tendency to compress or invade proximate structures of the prostate, so reductions of such tumors induced by ADT might lead to the improvement in LUTS. The effects of ADT might also relate to an overall shrinkage of the prostate because TPV was another factor related to LUTS relief. Mason et al. 25 reported that the efficacy of degarelix in terms of prostate shrinkage was similar to that of goserelin plus short-term bicalutamide (−36.0% TPV reduction in the degarelix group vs. −35.5% in the goserelin group at week 12) whereas degarelix showed benefit in terms of more pronounced LUTS relief than goserelin (−2.99 IPSS decrease in the degarelix group vs. −0.48 in the goserelin group at week 12) in patients with intermediate-to high-risk prostate cancer. The results of that study differed somewhat from the present study, in which patients were treated with goserelin and bicalutamide and experienced −37.5% TPV reduction and −2.4 IPSS decrease at week 12. Thus, the degree of LUTS relief may differ by the nature of the ADT.
In contrast to patients with moderate to severe LUTS, nocturia showed a significant increase during ADT therapy in patients with mild symptoms (Fig. 4e) . To the best of our knowledge, there has been no report of any association between ADT and nocturia, but several studies have demonstrated that there is an association between serum levels of testosterone and nocturia. Liao et al. 26 documented that nocturia showed a negative correlation with serum testosterone levels in men. Metabolic syndrome is associated with overactivity of the autonomic nervous system, which is considered to play a key role in increasing the severity of LUTS. 27 Nocturia has also been demonstrated to be associated with obesity and metabolic disorders. 28 ADT or low testosterone levels have been demonstrated to be associated with metabolic syndrome and obesity, 29, 30 so that development of metabolic syndrome or obesity by ADT might influence the severity of LUTS. Another possibility is that a low testosterone level might promote the onset of nocturnal polyuria in older patients because testosterone had been reported to play a physiological role in the maintenance of vasopression levels in rats and in the restoration of renal vasopressinbinding sites in aged rats. 31, 32 Because ADT suppresses serum levels of testosterone, it may induce dysregulation of the renal urine concentrating function by decreasing circulating vasopressin and vasopressin-biding sites in older men, resulting in the development of nocturnal polyuria. Recently, an association between testosterone levels and sleep quality has also been reported. In a cohort study of men aged 65 years and over, those with lower testosterone levels had reduced sleep efficiency, increased nocturnal awakenings, and less time in slow-wave sleep. 33 In mice, the loss of testosterone following gonadectomy results in a very small reduction in the amount of slow-wave sleep, which is increased by the replacement of testosterone. 34 However, it remains unclear how ADT increases nocturia in older men.
Our study had several limitations. First, it was done at a single center with a relatively small number of patients. Second, we did not investigate objective parameters, such as urodynamic studies or a bladder diary. However, our results provide the optimal duration to gain the maximal alleviation of LUTS in patients with moderate to severe LUTS, which may help to determine the duration of neoadjuvant ADT before brachytherapy or external beam radiotherapy. Furthermore, to the best of our knowledge, this is the first study to document an association between ADT and nocturia. Further studies are needed to verify these results and to clarify the mechanism involved, and such investigations should include a bladder diary, urodynamic studies, and measurements of serum vasopression and testosterone levels.
CONCLUSION
We observed that, in patients with moderate to severe LUTS, CAB reduced TPV and improved LUTS after 12 weeks of treatment, while further TPV reduction without a change in LUTS occurred from 12 to 24 weeks. In contrast, CAB increased nocturia in patients with mild LUTS despite reducing TPV.
